RECRUITING

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

Official Title

A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma

Quick Facts

Study Start:2022-06-01
Study Completion:2028-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05425004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Yazmin Odia, M.D.
CONTACT
(786) 596-2000
yazmino@baptisthealth.net
Anais Vega
CONTACT
(786) 596-2000
anais.vega@baptisthealth.net

Principal Investigator

Yazmin Odia, M.D.
PRINCIPAL_INVESTIGATOR
Miami Cancer Institute at Baptist Health, Inc.

Study Locations (Sites)

Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176
United States

Collaborators and Investigators

Sponsor: Baptist Health South Florida

  • Yazmin Odia, M.D., PRINCIPAL_INVESTIGATOR, Miami Cancer Institute at Baptist Health, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-01
Study Completion Date2028-05

Study Record Updates

Study Start Date2022-06-01
Study Completion Date2028-05

Terms related to this study

Keywords Provided by Researchers

  • Meningioma
  • central nervous system tumors
  • Recurrent meningioma
  • Progression meningioma

Additional Relevant MeSH Terms

  • Meningioma